Dr. Henri Huttunen is a biochemist and neurobiologist who has been studying the molecular mechanisms of neurodegeneration and developing new therapeutic approaches for slowing down disease progression in Parkinson’s disease (PD). He is a co-founder and chief scientific officer at Herantis Pharma Plc, located in Espoo, Finland. Herantis Pharma is developing HER-096, a compound that penetrates the blood-brain barrier and mimics a neurotrophic factor that protects dopamine neurons, as a disease-modifying therapy for PD. The company plans to start a Phase 1b study in 2024. Dr. Huttunen has previously held research positions at the University of Helsinki, Massachusetts General Hospital, Harvard Medical School and Orion Pharma Inc. He has published more than 60 peer-reviewed articles on novel therapeutic approaches and disease mechanisms related to both PD and Alzheimer’s disease, and he is an inventor on several related patents.